Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Short SellingSee which listed companies have disclosed short interest
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

BioInvent International

20.70 SEK-0.48 %28/10 17:29
Less than 1K followers

BINV

NASDAQ Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Short Selling
Investor views
Compare
-0.48 %
-8.81 %
-11.35 %
-3.94 %
-29.59 %
-26.86 %
+42.37 %
-43.47 %
-97.83 %

BioInvent International is a biotechnology company focused on the development of antibody therapies for cancer treatment. The company researches new treatments that can improve patient outcomes and quality of life. The company operates globally with a presence in international markets. BioInvent International was founded in 1983 and is headquartered in Lund.

Read more
Market cap
1.36B SEK
Turnover
3.18M SEK
Revenue
226.5M
EBIT %
-155.27 %
P/E
-
Dividend yield-%
-
Revenue and EBIT-%
EPS and dividend
Financial calendar
29/10
2026

Interim report Q3'26

All
Webcasts
Press releases
ShowingAll content types

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Regulatory press release2026-10-28 18:17

BioInvent International AB: Delårsrapport januari – september 2026

BioInvent International
Regulatory press release2026-10-28 18:17

BioInvent International AB: Interim report January – September, 2026

BioInvent International
Regulatory press release2026-10-28 18:16

Kallelse till extra bolagsstämma i BioInvent International AB

BioInvent International

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Regulatory press release2026-10-28 18:16

Notice to Extraordinary General Meeting in BioInvent International AB

BioInvent International
Regulatory press release2026-10-28 18:15

BioInvent beslutar om en företrädesemission om cirka 430 MSEK, under förutsättning av bolagsstämmans efterföljande godkännande, och tidigarelägger offentliggörandet av delårsrapport jan–sep 2026

BioInvent International
Regulatory press release2026-10-28 18:15

BioInvent resolves on a rights issue of approximately SEK 430 million subject to approval by an extraordinary general meeting and earlier publication of interim report January – September 2026

BioInvent International
Press release2026-10-27 14:15

Inbjudan till presentation av BioInvents delårsrapport januari-september 2026

BioInvent International
Press release2026-10-27 14:15

Invitation to presentation of BioInvent’s Interim Report January – September 2026

BioInvent International
Press release2026-10-26 15:17

Redeye: BioInvent: Larger Cohort Confirms BI-1808 Efficacy

BioInvent International
Regulatory press release2026-10-24 09:00

BioInvents BI-1808 och KEYTRUDA® ger varaktiga responser hos kraftigt förbehandlade patienter med platinaresistent äggstockscancer

BioInvent International
Regulatory press release2026-10-24 09:00

BioInvent's BI-1808 and KEYTRUDA® Induce Durable Responses in Heavily Pretreated Platinum-Resistant Ovarian Cancer

BioInvent International
Press release2026-10-19 14:22

Redeye: BioInvent: New RECIST Context to BI-1808 Data

BioInvent International
Press release2026-10-19 00:05

BioInvent kommer att presentera data för BI-1808 vid återfall i platinaresistent äggstockscancer på ESMO 2026

BioInvent International
Press release2026-10-19 00:05

BioInvent to present BI-1808 data in platinum-resistant recurrent ovarian cancer at ESMO 2026

BioInvent International
Press release2026-10-15 16:00

BioInvent publicerar data från den första kliniska studien med BI-1808 i tidskriften Clinical Cancer Research

BioInvent International
Press release2026-10-15 16:00

BioInvent Announces Publication of First-in-Human BI-1808 Data in Clinical Cancer Research

BioInvent International
Regulatory press release2026-10-12 09:45

BioInvent International AB meddelar att CFO går i pension 2027

BioInvent International
Regulatory press release2026-10-12 09:45

BioInvent International AB announces that its CFO will retire in 2027

BioInvent International
BioInvent, Audiocast, Q3'26
Webcast2026-10-29 15:00

BioInvent, Audiocast, Q3'26

BioInvent International
Press release2026-09-10 09:00

BioStock: BioInvent International to Present at Investing in Life Science on September 22

BioInvent International